Delivery Order SPE2DB24D1205-SPE2DB25FDALR
- Not listed
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,021.20 on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This is a firm fixed-price, non-set-aside competitive award with a performance location in Conshohocken, Pennsylvania, and an ultimate completion date of August 14, 2025. The delivery order represents a single transaction under AmerisourceBergen's larger federal contract vehicle with the Defense Logistics Agency. This delivery...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $12,823.53 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on September 12, 2025, with an ultimate completion date of September 15, 2025. This is a firm fixed price, non-competitive delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. HUMIRA is a widely used...
- The Defense Logistics Agency awarded a delivery order valued at $3,915.60 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on August 19, 2025, with completion scheduled for August 20, 2025. This delivery order represents a firm fixed-price procurement with no set-aside designation, competitively awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $10,599.37 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL under a firm fixed-price contract type. The delivery order was awarded competitively with no set-aside designation and carries an ultimate completion date of September 2, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL doses. This is a firm fixed price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. HUMIRA is a widely...
- The Defense Logistics Agency awarded a delivery order valued at $2,561.65 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction within...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDALRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,601.71 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on September 12, 2025, with an ultimate completion date of September 15, 2025. This is a firm fixed-price, non-set-aside contract with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle supporting federal pharmaceutical procurement needs. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. HUMIRA is a TNF-alpha inhibitor used to treat inflammatory conditions, and this procurement reflects DLA's ongoing acquisition of specialty pharmaceuticals for military beneficiaries and federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 9/12/25 |